{
    "clinical_study": {
        "@rank": "62207", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A:  Sufenta\u00ae IV", 
                "arm_group_type": "Active Comparator", 
                "description": "Sufenta\u00ae IV (50 mcg/mL) 30 mcg infused over 1 minute"
            }, 
            {
                "arm_group_label": "Treatment B:  SSM 30 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Single dose of SSM 30 mcg"
            }, 
            {
                "arm_group_label": "Treatment C:  2 consecutive doses of SSM 15 mcg", 
                "arm_group_type": "Experimental", 
                "description": "2 consecutive doses of SSM 15 mcg administered 20 minute apart"
            }, 
            {
                "arm_group_label": "Treatment D:  SSM 30 mcg", 
                "arm_group_type": "Experimental", 
                "description": "12 consecutive doses of SSM 30 mcg administered 1 hour apart"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the single and multiple-dose pharmacokinetics (PK)\n      of sublingual administration of the Sufentanil Sublingual Microtablet (SSM) 30 mcg and\n      compare the pharmacokinetics of a single dose of SSM 30 mcg to 2 doses of SSM 15 mcg\n      administered 20 minutes apart."
        }, 
        "brief_title": "Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Non-smoking male or female subjects\n\n          2. Aged between 18 and 45 years inclusive\n\n          3. Subjects must have Body Mass Index (BMI) between 18 and 30, inclusively.\n\n        Exclusion Criteria:\n\n          1. Subjects who are taking over-the-counter medication (except for single dose\n             multi-vitamin supplements or acetaminophen of less than 2 g/day) within 14 days prior\n             to start of sufentanil dosing prescription medications or over the counter (OTC)\n             medications\n\n          2. Female subjects who are pregnant\n\n          3. Subjects with chronic obstructive pulmonary disease, sleep apnea, or other\n             significant respiratory disorders"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02082236", 
            "org_study_id": "SAP101"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment A:  Sufenta\u00ae IV", 
                "intervention_name": "Treatment Arm A: Sufenta", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment B:  SSM 30 mcg", 
                "intervention_name": "Treatment B:  Sufentanil SSM 30 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment C:  2 consecutive doses of SSM 15 mcg", 
                "intervention_name": "Treatment C: 2 consecutive doses of SSM 15 mcg administered 20 minutes apart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment D:  SSM 30 mcg", 
                "description": "12 consecutive doses of SSM 30 mcg administered 1 hour apart", 
                "intervention_name": "Treatment D: SSM 30 mcg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sufentanil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Plasma concentrations", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66219"
                }, 
                "name": "PRA"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects", 
        "other_outcome": [
            {
                "description": "Maximum plasma concentration", 
                "measure": "C max", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "description": "Time to reach maximum plasma concentration", 
                "measure": "T max", 
                "safety_issue": "No", 
                "time_frame": "9 days"
            }, 
            {
                "measure": "Context Sensitive Half-Time  (CST\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "9 hours"
            }
        ], 
        "overall_official": {
            "affiliation": "PRA", 
            "last_name": "Sandra K. Willsie, D.O.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Area under the plasma concentration time curve", 
            "measure": "Area Under the Curve", 
            "safety_issue": "No", 
            "time_frame": "9 days, not including a 30 day screening window"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02082236"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AcelRx Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AcelRx Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}